Vectura Group plc Vectura to present at the J.P. Morgan Conference (7336T)

TIDMVEC

RNS Number : 7336T

Vectura Group plc

10 January 2017

Vectura Group plc

Vectura to present at the 35th Annual J.P. Morgan Healthcare Conference

Chippenham, UK - 10 January 2017: Vectura Group plc (LSE: VEC) ("Vectura") an industry-leading device and formulation business for inhaled airways disease, today announces that James Ward-Lilley, Vectura's CEO, is scheduled to present an overview of the business at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, 11 January 2017, at 3:30pm PST (11:30pm GMT).

A live webcast of the meeting and a copy of the presentation slides will be available on Vectura's website: http://www.vectura.com/investors/presentations-webcasts/. A recording will be available following the presentation.

- Ends -

Enquiries

 
Vectura Group plc                                                [phone] 
Andrew Derodra - Chief Financial Officer 
Fleur Wood - Director Communications 
Elizabeth Knowles - Director Investor Relations and Analysis 
 
Consilium Strategic Communications                               [phone] 
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson                  [e-mail] 
 
 

About Vectura

Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading inhaled airways disease focused business with proprietary formulation and devices across DPI, pMDI and "smart" nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases. In June 2016 Vectura completed a merger with Skyepharma PLC.

Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi, Almirall, Janssen, and Tianjin KingYork.

For further information, please visit Vectura's website at www.vectura.com.

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLKLLBDFFLBBQ

(END) Dow Jones Newswires

January 10, 2017 02:00 ET (07:00 GMT)